You have accessJournal of UrologyProstate Cancer: Staging II1 Apr 2016MP79-19 IMPACT OF INTRINSIC AND EXTRINSIC FACTORS ON THE DETECTION RATE OF THE PET TRACER FLUCICLOVINE (18F) IN BIOCHEMICAL RELAPSE OF PROSTATE CANCER: A MULTI-INSTITUTIONAL EXPERIENCE Trond Veld Bogsrud, Cristina Nanni, Peter Nieh, Lucia Zanoni, Tore Bach-Gansmo, H Sletten, K Koren, Jesse Kieboom, Albert Chau, Penny Ward, Mark Goodman, Stefano Fanti, David Schuster, and Frode Willoch Trond Veld BogsrudTrond Veld Bogsrud More articles by this author , Cristina NanniCristina Nanni More articles by this author , Peter NiehPeter Nieh More articles by this author , Lucia ZanoniLucia Zanoni More articles by this author , Tore Bach-GansmoTore Bach-Gansmo More articles by this author , H SlettenH Sletten More articles by this author , K KorenK Koren More articles by this author , Jesse KieboomJesse Kieboom More articles by this author , Albert ChauAlbert Chau More articles by this author , Penny WardPenny Ward More articles by this author , Mark GoodmanMark Goodman More articles by this author , Stefano FantiStefano Fanti More articles by this author , David SchusterDavid Schuster More articles by this author , and Frode WillochFrode Willoch More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2017AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Study BED001 retrospectively pooled and analysed data from an open access program in Oslo, Norway and 2 prospective studies conducted at Emory University, Atlanta, GA and Ospedale St'Orsola, Bologna Italy. This analysis evaluates the impact of intrinsic and extrinsic factors on fluciclovine (18F) PET-CT scan detection rate (DR) in a biochemical relapse (BR) cohort. Diagnostic performance compared to histology and clinical follow-up is reported separately. METHODS Data from 596 BR patients who underwent fluciclovine (18F) PET-CT scanning were subjected to subgroup analyses to evaluate the impact of: PSA at time of scanning, age, weight, race, prior treatment, Gleason and D'Amico risk scores on scan DR at a subject and region level. RESULTS BED001 was conducted in accordance with ICH GCP and the Declaration of Helsinki. Overall, fluciclovine (18F) PET-CT scanning detected sites of recurrence in 68% (403/595) of patients. The influence of baseline PSA value (by quartile) on DR is summarized below. The DR, at Subject level, was 41.4% for patients in the 1st quartile compared to >75% for those in the 3rd and 4th quartiles. DR at region level was 14% (PSA <0.79 ng/mL) compared to >50% (PSA >2.03 ng/mL) in the Prostate region (P), and 31% compared to 45-59% in the Extra-Prostatic region (E-P). Subgroup analyses to report performance against the other factors above will also be presented. CONCLUSIONS Results suggest that fluciclovine (18F) PET-CT is effective for visualising locations of prostate cancer relapse across a wide range of PSA values, including PSA <1ng/mL, with a Detection Rate proportional to PSA. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1041-e1042 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Trond Veld Bogsrud More articles by this author Cristina Nanni More articles by this author Peter Nieh More articles by this author Lucia Zanoni More articles by this author Tore Bach-Gansmo More articles by this author H Sletten More articles by this author K Koren More articles by this author Jesse Kieboom More articles by this author Albert Chau More articles by this author Penny Ward More articles by this author Mark Goodman More articles by this author Stefano Fanti More articles by this author David Schuster More articles by this author Frode Willoch More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract